BRPI0414930A - compostos e composições como inibidores de proteìnas cinases - Google Patents
compostos e composições como inibidores de proteìnas cinasesInfo
- Publication number
- BRPI0414930A BRPI0414930A BRPI0414930-0A BRPI0414930A BRPI0414930A BR PI0414930 A BRPI0414930 A BR PI0414930A BR PI0414930 A BRPI0414930 A BR PI0414930A BR PI0414930 A BRPI0414930 A BR PI0414930A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- inhibitors
- kinase
- raf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS E COMPOSIçõES COMO INIBIDORES DE PROTEìNAS CINASES". A presente invenção fornece uma classe inusitada de compostos, composições farmacêuticas que compreendem tais compostos, e métodos para usar tais compostos para tratar ou prevenir doenças ou distúrbios associados à atividade anormal ou desregulada de cinases, particularmente doenças ou distúrbios que envolvem a ativação anormal das cinases AbI, BCR-AbI, EGF-R, c-erbB2 cinase (HER2), CHK2, FGFR3, p70S6K, PKC, PDGF-R, p38, TGF<225>, KDR, c-Kit, b-RAF, c-RAF, FLT1 e/ou FLT4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50759203P | 2003-09-30 | 2003-09-30 | |
PCT/US2004/032473 WO2005033086A1 (en) | 2003-09-30 | 2004-09-30 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0414930A true BRPI0414930A (pt) | 2006-11-07 |
Family
ID=34421639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0414930-0A BRPI0414930A (pt) | 2003-09-30 | 2004-09-30 | compostos e composições como inibidores de proteìnas cinases |
Country Status (9)
Country | Link |
---|---|
US (1) | US7189729B2 (pt) |
EP (1) | EP1670771A4 (pt) |
JP (1) | JP2007507531A (pt) |
CN (1) | CN100412066C (pt) |
AU (1) | AU2004278413B2 (pt) |
BR (1) | BRPI0414930A (pt) |
CA (1) | CA2539339A1 (pt) |
MX (1) | MXPA06003557A (pt) |
WO (1) | WO2005033086A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
JP5097539B2 (ja) * | 2004-05-07 | 2012-12-12 | アムジエン・インコーポレーテツド | タンパク質キナーゼ調節剤および使用方法 |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
KR20080092412A (ko) * | 2006-02-06 | 2008-10-15 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
US20080125358A1 (en) * | 2006-10-26 | 2008-05-29 | University Of Massachusetts Medical School | Methods for Chk2 inhibitor patient selection |
US8236823B2 (en) | 2006-10-27 | 2012-08-07 | Amgen Inc. | Multi-cyclic compounds and methods of use |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
EP2170887A2 (en) | 2007-06-07 | 2010-04-07 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
EP2167497A2 (en) * | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Heterocyclic compounds useful as raf kinase inhibitors |
CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
DK2396307T3 (en) | 2009-02-11 | 2015-01-12 | Merck Patent Gmbh | NOVEL AMINO-azaheterocyclic carboxamides |
MX2012001413A (es) | 2009-08-07 | 2012-03-21 | Merck Patent Gmbh | Compuestos azaheterociclicos novedosos. |
US8728763B2 (en) | 2009-08-11 | 2014-05-20 | Response Genetics | Methods, primers, probes and kits useful for the detection of BRAF mutations |
US20130079345A1 (en) * | 2010-03-22 | 2013-03-28 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
UA110113C2 (xx) | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
WO2012016001A1 (en) | 2010-07-29 | 2012-02-02 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
MX355325B (es) | 2010-11-24 | 2018-04-16 | Merck Patent Gmbh | Quinazolincarboxamida azetidinas. |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
SI2755965T1 (sl) | 2011-09-12 | 2017-12-29 | Merck Patent Gmbh | Novi imidazolni amidi kot modulatorji kinazne aktivnosti |
LT2755958T (lt) | 2011-09-12 | 2017-11-10 | Merck Patent Gmbh | Aminopirimidino dariniai, skirti naudoti kaip kinazės aktyvumo moduliatoriai |
BR112014012396B1 (pt) | 2011-11-23 | 2020-08-25 | Portola Pharmaceuticals, Inc | inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit |
MX353062B (es) | 2011-12-22 | 2017-12-19 | Merck Patent Gmbh | Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas. |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
EP2920178B1 (en) | 2012-11-16 | 2016-12-21 | Merck Patent GmbH | Novel heterocyclic derivatives as modulators of kinase activity (p70s6 and akt) |
JP6280130B2 (ja) | 2012-11-16 | 2018-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体 |
BR112015011974A8 (pt) | 2012-11-29 | 2019-10-08 | Merck Patent Gmbh | derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica |
EP2970201B1 (en) | 2013-03-11 | 2019-06-19 | Merck Patent GmbH | 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
BR112016020135A8 (pt) | 2014-04-03 | 2021-07-06 | Merck Patent Gmbh | mistura de composto, seus usos, composição farmacêutica, e conjunto (kit) |
CN113164478A (zh) * | 2018-09-13 | 2021-07-23 | 南加州大学 | 新型fgfr抑制剂及其用途 |
WO2022101459A1 (en) | 2020-11-16 | 2022-05-19 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511378A (ja) * | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
CN1429222A (zh) * | 2000-02-17 | 2003-07-09 | 安姆根有限公司 | 激酶抑制剂 |
-
2004
- 2004-09-30 JP JP2006534171A patent/JP2007507531A/ja active Pending
- 2004-09-30 BR BRPI0414930-0A patent/BRPI0414930A/pt not_active IP Right Cessation
- 2004-09-30 US US10/956,412 patent/US7189729B2/en not_active Expired - Fee Related
- 2004-09-30 CA CA002539339A patent/CA2539339A1/en not_active Abandoned
- 2004-09-30 WO PCT/US2004/032473 patent/WO2005033086A1/en active Search and Examination
- 2004-09-30 MX MXPA06003557A patent/MXPA06003557A/es active IP Right Grant
- 2004-09-30 EP EP04789483A patent/EP1670771A4/en not_active Withdrawn
- 2004-09-30 CN CNB2004800284506A patent/CN100412066C/zh not_active Expired - Fee Related
- 2004-09-30 AU AU2004278413A patent/AU2004278413B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP1670771A1 (en) | 2006-06-21 |
CN1860106A (zh) | 2006-11-08 |
WO2005033086A1 (en) | 2005-04-14 |
AU2004278413A1 (en) | 2005-04-14 |
EP1670771A4 (en) | 2010-09-01 |
CN100412066C (zh) | 2008-08-20 |
US20050171105A1 (en) | 2005-08-04 |
MXPA06003557A (es) | 2006-06-20 |
AU2004278413B2 (en) | 2008-07-31 |
JP2007507531A (ja) | 2007-03-29 |
US7189729B2 (en) | 2007-03-13 |
CA2539339A1 (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414930A (pt) | compostos e composições como inibidores de proteìnas cinases | |
BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
BRPI0507668A (pt) | compostos e composições como inibidores de proteìna cinase | |
BRPI0409173A (pt) | compostos e composições como inibidores de proteìna quinase | |
BRPI0511978A (pt) | compostos e composições como inibidores de proteìnas quinases | |
WO2006105516A3 (en) | Compositions and methods for diagnosing and treating neuropsychiatric disorders | |
BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
EA201070012A1 (ru) | МЕТАБОЛИТЫ (R)-3-(4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1H-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА, ИНГИБИТОРА JANUS КИНАЗ | |
MA30888B1 (fr) | Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr) | |
LTPA2016034I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
NO20091989L (no) | Forbindelser som modulerer c-fms og/eller C-kit aktivitet og deres anvendelse | |
ATE469151T1 (de) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
BRPI0512422A (pt) | compostos e composições como inobidores da proteìna quinase | |
BRPI0719797A8 (pt) | Compostos e composições como inibidores de proteína cinase | |
BRPI0414049A (pt) | compostos e composições como inibidores de proteìna cinase | |
BR0215429A (pt) | Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente | |
MA31153B1 (fr) | Composés et méthodes pour moduler une kinase et indications associées | |
NO20072887L (no) | Forbindelser og sammensetninger som protein kinase inhibitorer | |
DE602004028286D1 (de) | Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen | |
MX2008002165A (es) | Compuestos y composiciones como inhibidores de la proteina cinasa. | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
TW200616632A (en) | Compounds modulating c-kit activity and uses therefor | |
BR0317110A (pt) | Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos | |
MX2022004937A (es) | Inhibidores de las cinasas raf. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE. |